v3.24.1.u1
Investments and Other Assets - Additional Information (Detail) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]      
Reclassification of other comprehensive loss - equity method investment $ 2,132,000    
Investments and other assets 70,957,000   $ 42,883,000
Change in fair value of investments, net (6,065,000) $ 0  
Collaboration revenue 28,935,000 12,606,000  
Accrued expenses 43,276,000   67,017,000
AvenCell Therapeutics, Inc. [Member]      
Schedule of Equity Method Investments [Line Items]      
Reclassification of other comprehensive loss - equity method investment 2,100,000    
Investments and other assets 9,600,000    
Kyverna Therapeutics Inc [Member]      
Schedule of Equity Method Investments [Line Items]      
Investment Owned, Balance, Principal Amount 29,200,000    
Change in fair value of investments, net 19,200,000    
Investment Owned, Fair Value     10,000,000
AvenCell [Member]      
Schedule of Equity Method Investments [Line Items]      
Change in fair value of investments, net 25,300,000    
Investment Owned, Fair Value     $ 11,800,000
Collaboration revenue 21,000,000 4,900,000  
Accounts receivable 200,000    
Accrued expenses $ 1,000,000    
AvenCell [Member] | AvenCell Therapeutics, Inc. [Member]      
Schedule of Equity Method Investments [Line Items]      
Equity method investment, ownership percentage 33.33%   33.33%
Collaboration revenue $ 0    
Sparing Vision [Member]      
Schedule of Equity Method Investments [Line Items]      
Investment Owned, Fair Value 14,600,000    
Collaboration revenue $ 500,000 $ 400,000